RavenQuest Announces Change to Board of Directors
Email Print Friendly Share
November 29, 2019 17:34 ET | Source: RavenQuest BioMed Inc.
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), today announced that Cassidy McCord has been appointed director of the Company. Ms. McCord’s bio can be found below. RavenQuest further announces the resignation from the board of Mark Ahrens-Townsend.
“As RavenQuest evolves toward profitability, the composition of our board has taken shape to reflect our plans for 2020 and beyond," said George Robinson, RavenQuest CEO. "To fully realize our potential moving forward, I’m confident recent changes at the board level will provide impactful leadership and perspective as we transition from a start-up into an operating company.” Robinson continued.
Cassidy McCord
Ms. McCord has a medicinal cannabis background, focusing on company reorganization and patient processing. She has also held the position of director for a publicly traded cannabis company and also holds a business administration diploma from Vancouver Island University
For more information, access RavenQuest’s investor presentation, fact sheet and videos here.
Follow RavenQuest:
Twitter
Instagram
Facebook
LinkedIn
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson”
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications
1-877-282-1586
